- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06282588
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER)
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/ 3 Trial
This Investigator-initiated, Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER) study will be conducted in subjects with high-risk localized or locally advanced prostate cancer (PCa). The study contains both a randomized Phase 3 treatment intensification study, as well as a treatment de-intensification non-randomized Phase 2 study. The aim of the THUNDER study is to improve the outcome of high-risk PCa by improved risk stratification. Novel radiotracers and a genomic classifier (Decipher) will be used to guide treatment decisions, instead of standard imaging which is limited by lower sensitivity and specificity.
The hypothesis for the study is that treatment intensification based on a positive PSMA PET/ CT scan or Decipher high score (> 0.6) improves time to new metastases detected on PSMA PET/ CT in high-risk PCa. In patients who are PSMA PET/ CT negative with a low/ intermediate Decipher score (≤ 0.6), it is hypothesized that treatment de-intensification will improve patient quality of life while maintaining a good oncological outcome.
The study will be conducted at multiple centers across Europe. Participation in the study will comprise a screening period, where the screening assessments must be completed before subjects are enrolled and randomized (only for Phase 3 subjects). Eligible, consenting subjects will then undergo treatment according to their assigned study phase and treatment group, to occur over up to 96 weeks (24 months) with a post-treatment follow-up period to monitor safety and efficacy. The study will be closed when 96 events have been registered for the primary endpoint, which is expected to be at 7-8 years from the time of randomization of the first subject.
Study Overview
Status
Conditions
Intervention / Treatment
- Drug: Darolutamide
- Radiation: Radiotherapy
- Drug: Zoladex 3.6Mg Implant
- Drug: Zoladex LA
- Drug: Decapeptyl sustained release 22.5 mg
- Drug: Decapeptyl sustained release 11.25 mg
- Drug: Depo-Eligard 45 mg
- Drug: Depo-Eligard 22.5 mg
- Drug: Depo-Eligard 7.5 mg
- Drug: Firmagon 120 MG Injection
- Drug: Firmagon 80 MG Injection
- Drug: Docetaxel
- Drug: Darolutamide matched placebo
Detailed Description
Approximately 360 evaluable patients determined to have high-risk localized or locally advanced PCa, with PSMA positive non-localized disease or a Decipher high score (> 0.6) will be enrolled to the Phase 3 trial. Subjects with PSMA positive non-localized disease for which a Decipher result cannot be obtained, will also be enrolled to the Phase 3 study.
All Phase 3 subjects will be randomly assigned in a 1:1 ratio to receive darolutamide plus Luteinizing hormone releasing hormone (ant)-agonists (LHRHA), or darolutamide matched placebo plus LHRHA, for up to 96 weeks (24 months). All Phase 3 subjects will also receive primary standard of care (SOC) radiation therapy (RT). Subjects in Phase 3 should be commenced on an LHRHA and darolutamide or placebo within 14 days after randomization (unless started earlier) plus SOC RT. Only patients with a PSMA PET-CT showing more than 5 M1 lesions are allowed to receive docetaxel in both arms of the Phase 3 trial. Docetaxel should be started within 4 weeks from randomization. Randomization of Phase 3 subjects will be stratified by 1 versus > 1 high-risk features, N1 versus M1 PSMA positive versus PSMA negative disease, Decipher low/ intermediate versus high versus unknown score and clinical trial site.
Approximately 133 evaluable patients determined to have localized PCa by PSMA PET/ CT (PSMA negative) with a low/ intermediate Decipher test score (≤ 0.6) will enter the non-randomized, Phase 2, single treatment arm, de-intensification study. Subjects with localized PCa by PSMA PET/ CT who return a high Decipher score (> 0.6) will be enrolled and randomized into the Phase 3 study. Subjects with localized PCa by PSMA PET/ CT for which a Decipher result cannot be obtained, will be deemed ineligible for study participation.
All Phase 2 study subjects will receive darolutamide for the study duration for up to 96 weeks (24 months) and primary SOC RT.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Piet Ost, MD, PhD
- Phone Number: 003234433759
- Email: cancertrials@gza.be
Study Locations
-
-
-
Aalst, Belgium, 9300
- Not yet recruiting
- OLVZ Aalst
-
Contact:
- Samuel Br
-
Principal Investigator:
- Samuel Bral
-
Brugge, Belgium, 8000
- Not yet recruiting
- AZ Sint-Jan
-
Contact:
- Sabine Meersschout
-
Principal Investigator:
- Sabine Meersschout
-
Bruxelles, Belgium, 1200
- Not yet recruiting
- Saint Luc
-
Contact:
- Ad Vanderm
-
Principal Investigator:
- Ad Vandermeulen
-
Edegem, Belgium, 2600
- Not yet recruiting
- UZA
-
Contact:
- Karen Fransis
-
Principal Investigator:
- Karen Fran
-
Gent, Belgium, 9000
- Not yet recruiting
- UZ Gent
-
Contact:
- Valérie Fonteyne
-
Principal Investigator:
- Valérie Fonteyne
-
Gent, Belgium, 900
- Not yet recruiting
- AZ Sint-Lucas
-
Contact:
- Lien Van De Voorde
-
Principal Investigator:
- Lien Van De Voor
-
Kortrijk, Belgium, 8500
- Not yet recruiting
- AZ Groeninge
-
Contact:
- Nick Liefhooghe
-
Principal Investigator:
- Nick Liefhooghe
-
Liège, Belgium, 4000
- Not yet recruiting
- CHU Liege
-
Principal Investigator:
- Brieuc Sautois
-
Contact:
- Brieuc Suatois
-
Roeselare, Belgium, 8800
- Not yet recruiting
- AZ DELTA
-
Contact:
- Benedikt Engels
-
Principal Investigator:
- Benedikt Enge
-
Sint-Niklaas, Belgium, 9100
- Not yet recruiting
- Vitaz
-
Contact:
- Bart De Troyer
-
Principal Investigator:
- Bart De Troyer
-
-
Antwerp
-
Wilrijk, Antwerp, Belgium, 2610
- Recruiting
- GZA Sint-Augustinus
-
Contact:
- Piet Ost, MD, PhD
- Email: cancertrials@gza.be
-
Principal Investigator:
- Piet Ost
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histopathology-proven PCa
High-risk locally advanced disease is defined as any of the following factors: PSA > 20 ng/mL OR T-stage 3 or 4 OR Gleason score 8-10 OR cN1.
Note: documentation of the clinical T-stage may be obtained from any clinical assessment acceptable for clinical T staging including physical exam (DRE), transrectal ultrasound, CT or MRI. Documentation for the N1 stage can be defined on CT or MRI.
- An Eastern Cooperative Oncology Group (ECOG) Performance Status grade of 0 or 1.
Willingness to undergo a PSMA PET/ CT with or without contrast.
- Subjects who are PSMA PET/ CT positive for at least one regional or distant (extra-pelvic) lesion at screening (PSMA PET scans will be assessed as described in the study imaging manual), will be eligible to be randomized to either arm of the Phase 3 study. A lesion is considered positive if it has a E-PMSA score of 4 or 5.
- Pending confirmation of their Decipher score, subjects who are PSMA PET/ CTnegative for regional or distant lesions at screening (PSMA PET scans will be assessed as described in the study imaging manual), will be eligible for inclusion in either the Phase 3 study (if a high [> 0.6] Decipher score is confirmed) or the non-randomized Phase 2 study (if a low/ intermediate [≤ 0.6] Decipher score is confirmed).
Willingness to have their primary tumor sequenced for determination of Decipher score
- Subjects who have a negative PSMA PET/ CT and a tumor with a low/ intermediate Decipher score (≤ 0.6) will be eligible to enter the non-randomized Phase 2 study.
- Subjects who have a negative PSMA PET/ CT and a tumor with a high Decipher score (> 0.6) will be eligible to be randomized to either arm of the Phase 3 study.
- In subjects with positive PSMA PET/ CT, the Decipher score will not determine the treatment allocation.
- Willingness to undergo SOC RT and long-term ADT (treatment with darolutamide and/ or LHRHA)
- Subject is able and willing to provide written informed consent, which includes compliance with and ability to undergo all study procedures and attend the scheduled follow-up visit/s per protocol.
- Subject must be over 18 years of age.
- Subject able to swallow whole study drug tablets.
- To avoid risk of drug exposure through the ejaculate (even men with vasectomies), subjects must use a condom during sexual activity while on study drug and for 3 months after the last administration of study treatment. Donation of sperm is not allowed during the treatment phase and for 3 months after the last administration of study treatment.
Adequate organ function determined by the following local laboratory values:
- Adequate bone marrow function: Hemoglobin ≥ 100 g/L, white cell count (WCC) ≥ 4.0 x 109/L, absolute neutrophil count (ANC) ≥ 1.5 x 109/L and platelets > 100 x 109/L
- Adequate renal function: calculated creatinine clearance > 30 mL/min (Cockroft-Gault)
- Adequate liver function: ALT < 2 x upper limit of normal (ULN) and total bilirubin < 1.5 x ULN, (or if total bilirubin is between 1.5 to 2 x ULN, they must have a normal conjugated bilirubin)
- Testosterone levels > 50 ng/dL
Exclusion Criteria:
- Definitive radiologic evidence of metastatic disease outside of the pelvic nodes (M1a, M1b or M1c) on conventional imaging (i.e., bone scan, CT scan, MRI)
- PCa with predominant non-adenocarcinoma features (sarcomatoid or spindle or neuroendocrine small cell or squamous cell components or other non-adenocarcinoma)
- Prior pelvic radiotherapy
- Contraindications for pelvic radiotherapy
- Contraindications for ADT (treatment with darolutamide and/ or LHRHA)
- Contraindications or known allergy to PSMA PET/ CT tracers.
- Prior local therapy for PCa (e.g., radical prostatectomy, high-intensity focused ultrasound [HIFU], cryotherapy). Subjects with previous transurethral resection of the prostate (TURP) or Millin prostatectomy are eligible for participation
- Prior systemic therapy for PCa, except for patients with a positive PSMA PET/ CT staging with ADT started no more than 4 weeks prior to randomization.
- Current use of 5-alpha reductase inhibitor Note: if the alpha reductase inhibitor is stopped ≥ 2 weeks prior to enrollment, the subject is eligible.
- Current chronic use of opioid analgesics, for ≥3 weeks for oral or ≥7 days for non-oral formulations
- History of seizure or any condition that may predispose to seizure (including, but not limited to prior stroke, transient ischemic attack or loss of consciousness within ≤1 year prior to enrollment; brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect)
- Any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject
- Major surgery within 21 days prior to enrollment.
History of:
- Loss of consciousness or transient ischemic attack or stroke within 6 months prior to enrollment, or
- Significant cardiovascular disease within 6 months prior to enrollment: including myocardial infarction, unstable angina, congestive heart failure (New York Heart Association [NYHA] classification Grade 2 or greater), ongoing arrhythmias of Grade > 2 (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] v5.0), thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism), coronary artery bypass graft. Chronic stable atrial fibrillation on stable anticoagulant therapy is allowed.
- Known GI disease or GI procedure that could interfere with the oral absorption or tolerance of darolutamide, including difficulty swallowing tablets
- History of another malignancy within 5 years prior to enrollment except for those malignancies treated with curative intent with a predicted risk of relapse of less than 10% including but not limited to non-melanoma carcinoma of the skin; or adequately treated, non-muscle-invasive urothelial carcinoma of the bladder (i.e., Tis, Ta and low grade T1 tumors). All such cases with a history of malignancy within the last 5 years are to be discussed with study team before enrollment. Melanoma in-situ and other adequately treated in-situ neoplasms are not considered malignancies for the purposes of eligibility assessment
- Concurrent illness, including severe infection that might jeopardize the ability of the subject to undergo the procedures outlined in this protocol with reasonable safety (human immunodeficiency virus [HIV] infection is not an exclusion criterion if it is controlled with anti-retroviral drugs that are unaffected by concomitant darolutamide)
- Subjects who are sexually active with women of childbearing potential and not willing/able to use medically acceptable and highly effective forms of contraception during study treatment and for at least 3 months after the last administration of study treatment. Contraception must include: Additional birth control with low failure rate (less than 1% per year) when used consistently and correctly, e.g., combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device (IUD), intrauterine hormone releasing system (IUS), bilateral tubal occlusion, vasectomized partner, true sexual abstinence.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 2 Open Label
Darolutamide for up to 96 weeks (24 months) and primary SOC RT
|
2x300 mg tablets twice daily, for up to 96 weeks
Other Names:
Preferred regimens: 60 to 62 Gy delivered in 20 fractions of 3.0 to 3.1Gy per fraction; 36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction, 2-3 fractions per week
|
Experimental: Phase 3 Blinded Experimental
Darolutamide + LHRHA for up to 96 weeks (24 months) and primary SOC RT
|
2x300 mg tablets twice daily, for up to 96 weeks
Other Names:
Preferred regimens: 60 to 62 Gy delivered in 20 fractions of 3.0 to 3.1Gy per fraction; 36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction, 2-3 fractions per week
3.6 mg, subcutaneous use
Other Names:
10.8 mg, subcutaneous use
Other Names:
22.5 mg, intramusculair injection
Other Names:
11.25 mg, intramusculair injection
Other Names:
45 mg, subcutaneous use
Other Names:
22.5 mg, subcutaneous use
Other Names:
7.5 mg, subcutaneous use
Other Names:
120 mg, subcutaneous use
Other Names:
80 mg, subcutaneous use
Other Names:
75 mg per square m, IV infusion
Other Names:
|
Placebo Comparator: Phase 3 Blinded Comparator
Darolutamide matched placebo + LHRHA for up to 96 weeks (24 months) and primary SOC RT
|
Preferred regimens: 60 to 62 Gy delivered in 20 fractions of 3.0 to 3.1Gy per fraction; 36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction, 2-3 fractions per week
3.6 mg, subcutaneous use
Other Names:
10.8 mg, subcutaneous use
Other Names:
22.5 mg, intramusculair injection
Other Names:
11.25 mg, intramusculair injection
Other Names:
45 mg, subcutaneous use
Other Names:
22.5 mg, subcutaneous use
Other Names:
7.5 mg, subcutaneous use
Other Names:
120 mg, subcutaneous use
Other Names:
80 mg, subcutaneous use
Other Names:
75 mg per square m, IV infusion
Other Names:
2x300 mg tablets twice daily, for up to 96 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 3: PSMA PET metastasis free survival (ppMFS)
Time Frame: Time from randomization to the date of at least 1 new PSMA-PET positive distant lesion as compared to baseline or date of death from any cause, assessed up to 42 months
|
Improvement in PSMA PET metastasis free survival (ppMFS)
|
Time from randomization to the date of at least 1 new PSMA-PET positive distant lesion as compared to baseline or date of death from any cause, assessed up to 42 months
|
Phase 2: quality of life (sexual subdomain)
Time Frame: At 12 months
|
EPIC mean changes in sexual subdomain scores over time will be compared, both for change from baseline and absolute scores
|
At 12 months
|
Phase 2: quality of life (hormonal subdomain)
Time Frame: At 12 months
|
EPIC mean changes in hormonal subdomain scores over time will be compared, both for change from baseline and absolute scores
|
At 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: Time interval between randomization and time of death, assessed up to 42 months
|
Overall survival
|
Time interval between randomization and time of death, assessed up to 42 months
|
Prostate-cancer specific survival
Time Frame: Time interval between randomization and prostate cancer death, assessed up to 42 months
|
Prostate-cancer specific survival
|
Time interval between randomization and prostate cancer death, assessed up to 42 months
|
Biochemical progression-free survival
Time Frame: Measured from the date of randomization to the date event, or death or censored at the last known follow-up date, assessed up to 42 months
|
Increase in PSA of >2 ng/ml above the nadir PSA level
|
Measured from the date of randomization to the date event, or death or censored at the last known follow-up date, assessed up to 42 months
|
Time to next systemic therapy
Time Frame: Measured from date of randomization to time of death, or censored at the last known follow-up date, assessed up to 42 months
|
Time to next systemic therapy
|
Measured from date of randomization to time of death, or censored at the last known follow-up date, assessed up to 42 months
|
Frequency and severity of adverse events
Time Frame: From signing ICF until 30 days after the last dose of study treatment.
|
Frequency and severity of adverse events
|
From signing ICF until 30 days after the last dose of study treatment.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Piet Ost, MD,PhD, Gasthuis Zusters Antwerpen
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Prostatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Hormonal
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptive Agents, Female
- Fertility Agents, Female
- Fertility Agents
- Luteolytic Agents
- Docetaxel
- Leuprolide
- Goserelin
- Triptorelin Pamoate
Other Study ID Numbers
- CTO21042GZA
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingProstate Adenocarcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer... and other conditionsUnited States
Clinical Trials on Darolutamide
-
BayerCompletedCerebrovascular CirculationUnited Kingdom
-
The First Affiliated Hospital with Nanjing Medical...RecruitingMetastatic Prostate Cancer | Intermitent Anti-androgen TherapyChina
-
Association Pour La Recherche des Thérapeutiques...BayerRecruiting
-
Peking University First HospitalThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical... and other collaboratorsRecruiting
-
AstraZenecaRecruitingProstate CancerUnited States, Spain, United Kingdom, Netherlands, Canada, Australia
-
BayerRecruitingBiochemically Recurrent Prostate CancerAustria, Spain, United States, Australia, Brazil, France, Germany, Taiwan, Denmark, China, Netherlands, Portugal, Japan, Canada, Finland, Italy, Hungary, United Kingdom, Poland, Israel, New Zealand, Sweden, Belgium, Czechia
-
BayerActive, not recruitingProstate CancerUnited States, Canada, Japan, Spain, Germany, Belgium, Argentina, Austria, Brazil, Greece, Italy, Russian Federation, Taiwan, China, Denmark, France, Colombia
-
BayerTerminatedProstatic Cancer, Castration-ResistantUnited States
-
D'Or Institute for Research and EducationBayer; RPH Central PharmaRecruiting
-
BayerRecruitingCancerKorea, Republic of, United States, China, Austria, Belgium, Brazil, Colombia, Czechia, Estonia, Finland, France, Germany, Hungary, Israel, Italy, Japan, Latvia, Lithuania, Netherlands, Peru, Poland, Portugal, Romania, Russian Federation, Slovak... and more